MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, announced that MSD has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. Read more.